Oxalo Therapeutics is developing first-in-class peptide therapeutics to treat primary hyperoxaluria, a rare genetic disorder that leads to excessive oxalate production and recurrent kidney stones. The company aims to replicate the oxalate-regulating mechanism of the gut microbe Oxalobacter formigenes to improve kidney health in affected patients.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Primary hyperoxaluria is a rare genetic disorder characterized by excessive oxalate production, leading to recurrent kidney stone formation, nephrocalcinosis, and potentially end-stage renal disease. Current treatment options are limited, leaving a significant unmet need for effective therapies. The disease affects an estimated 5,000 patients in the U.S. and E.U.
Solution
Oxalo Therapeutics is developing first-in-class peptide therapeutics designed to address primary hyperoxaluria and other oxalate-related pathologies. The company's approach is inspired by the oxalate-regulating mechanism of the gut microbe *Oxalobacter formigenes*. By replicating this natural process, Oxalo aims to restore oxalate homeostasis and prevent the severe kidney complications associated with the disease. Their therapeutic strategy focuses on modulating oxalate levels to preserve long-term kidney health in affected individuals.
Target Audience
The primary target audience includes patients diagnosed with primary hyperoxaluria, a rare genetic disorder affecting kidney health, and potentially individuals with other oxalate-related kidney diseases.
Features
- First-in-class peptide therapeutics targeting oxalate production.
- Mimics the natural oxalate-regulating mechanism of *Oxalobacter formigenes*.
- Designed to restore oxalate homeostasis.
- Aims to prevent recurrent kidney stones and nephrocalcinosis.
- Focuses on preserving long-term kidney health.